NasdaqGM - Nasdaq Real Time Price USD

Harvard Bioscience, Inc. (HBIO)

Compare
2.0200
+0.0400
+(2.02%)
At close: January 14 at 4:00:01 PM EST
Loading Chart for HBIO
DELL
  • Previous Close 1.9800
  • Open 2.0000
  • Bid 1.9800 x 100
  • Ask 2.0500 x 100
  • Day's Range 1.9600 - 2.0600
  • 52 Week Range 1.8100 - 4.9300
  • Volume 185,698
  • Avg. Volume 190,535
  • Market Cap (intraday) 88.106M
  • Beta (5Y Monthly) 1.31
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3300
  • Earnings Date Mar 5, 2025 - Mar 10, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.25

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

www.harvardbioscience.com

391

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HBIO

View More

Performance Overview: HBIO

Trailing total returns as of 1/14/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

HBIO
0.00%
S&P 500
1.08%

1-Year Return

HBIO
58.78%
S&P 500
22.14%

3-Year Return

HBIO
67.83%
S&P 500
25.41%

5-Year Return

HBIO
35.67%
S&P 500
77.70%

Compare To: HBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HBIO

View More

Valuation Measures

Annual
As of 1/14/2025
  • Market Cap

    88.11M

  • Enterprise Value

    129.23M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.89

  • Price/Book (mrq)

    1.35

  • Enterprise Value/Revenue

    1.32

  • Enterprise Value/EBITDA

    179.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -14.57%

  • Return on Assets (ttm)

    -1.98%

  • Return on Equity (ttm)

    -20.40%

  • Revenue (ttm)

    97.73M

  • Net Income Avi to Common (ttm)

    -14.24M

  • Diluted EPS (ttm)

    -0.3300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.57M

  • Total Debt/Equity (mrq)

    70.29%

  • Levered Free Cash Flow (ttm)

    6.06M

Research Analysis: HBIO

View More

Company Insights: HBIO

Research Reports: HBIO

View More

People Also Watch